At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
Poliorixbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.
In Brief
A Phase 1 clinical trial evaluating Poliorix for Poliomyelitis. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoliomyelitis
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartAug 2009
Primary CompletionNov 2009
TodayJul 2026
First PostedJul 13, 2009
Enrollment StartAug 4, 2009
Primary CompletionNov 13, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.0 years ago
Interventions
Poliorixbiological
All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.